These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

301 related articles for article (PubMed ID: 22364129)

  • 21. The lipid paradox in rheumatoid arthritis: the dark horse of the augmented cardiovascular risk.
    Venetsanopoulou AI; Pelechas E; Voulgari PV; Drosos AA
    Rheumatol Int; 2020 Aug; 40(8):1181-1191. PubMed ID: 32524301
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Therapy Insight: managing cardiovascular risk in patients with rheumatoid arthritis.
    Giles JT; Post W; Blumenthal RS; Bathon JM
    Nat Clin Pract Rheumatol; 2006 Jun; 2(6):320-9. PubMed ID: 16932711
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cardiovascular risk in rheumatoid arthritis: effects of anti-TNF drugs.
    Avouac J; Allanore Y
    Expert Opin Pharmacother; 2008 May; 9(7):1121-8. PubMed ID: 18422470
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Chronic inflammation increases the risk of cardiovascular disease in patients with rheumatoid arthritis].
    Troelsen LN; Jacobsen S
    Ugeskr Laeger; 2006 Sep; 168(39):3304-8. PubMed ID: 17032593
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prevention of cardiovascular disease in rheumatoid arthritis.
    Hollan I; Dessein PH; Ronda N; Wasko MC; Svenungsson E; Agewall S; Cohen-Tervaert JW; Maki-Petaja K; Grundtvig M; Karpouzas GA; Meroni PL
    Autoimmun Rev; 2015 Oct; 14(10):952-69. PubMed ID: 26117596
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cardiovascular disease in rheumatoid arthritis: disease and treatment interactions and their implications on treatment decisions.
    Sanders S; Geraci SA
    J Miss State Med Assoc; 2010 Mar; 51(3):75-80. PubMed ID: 20827876
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cardiovascular Risk in Rheumatoid Arthritis and Mechanistic Links: From Pathophysiology to Treatment.
    Fragoulis GE; Panayotidis I; Nikiphorou E
    Curr Vasc Pharmacol; 2020; 18(5):431-446. PubMed ID: 31258091
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cardiovascular risk in rheumatoid arthritis.
    Soubrier M; Barber Chamoux N; Tatar Z; Couderc M; Dubost JJ; Mathieu S
    Joint Bone Spine; 2014 Jul; 81(4):298-302. PubMed ID: 24880190
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cardiovascular outcomes of patients with rheumatoid arthritis prescribed disease modifying anti-rheumatic drugs: a review.
    Giollo A; Bissell LA; Buch MH
    Expert Opin Drug Saf; 2018 Jul; 17(7):697-708. PubMed ID: 29871535
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cardiovascular disease in rheumatoid arthritis.
    Gonzalez-Gay MA; Gonzalez-Juanatey C; Miranda-Filloy JA; Garcia-Porrua C; Llorca J; Martin J
    Biomed Pharmacother; 2006 Dec; 60(10):673-7. PubMed ID: 17049201
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Microvascular endothelial dysfunction in rheumatoid arthritis.
    Bordy R; Totoson P; Prati C; Marie C; Wendling D; Demougeot C
    Nat Rev Rheumatol; 2018 Jul; 14(7):404-420. PubMed ID: 29855620
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Cardiovascular disorders in rheumatoid arthritis].
    Morović-Vergles J
    Reumatizam; 2008; 55(2):53-6. PubMed ID: 19024275
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Targeting cardiovascular risk in rheumatoid arthritis: a dual role for statins.
    Bisoendial RJ; Stroes ES; Kastelein JJ; Tak PP
    Nat Rev Rheumatol; 2010 Mar; 6(3):157-64. PubMed ID: 20142814
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cardiovascular effects of methotrexate in rheumatoid arthritis revisited.
    Popkova TV; Novikova DS; Gasparyan AY; Nasonov EL
    Curr Med Chem; 2015; 22(16):1903-10. PubMed ID: 25876749
    [TBL] [Abstract][Full Text] [Related]  

  • 35. How early in the course of rheumatoid arthritis does the excess cardiovascular risk appear?
    Kerola AM; Kauppi MJ; Kerola T; Nieminen TV
    Ann Rheum Dis; 2012 Oct; 71(10):1606-15. PubMed ID: 22736093
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The management of cardiovascular disease risk in patients with rheumatoid arthritis.
    Ahmed O; Krishnamurthy V; Kaba RA; Tahir H
    Expert Opin Pharmacother; 2022 Jun; 23(8):947-958. PubMed ID: 35575484
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cardiovascular morbidity and mortality in patients with rheumatoid arthritis: vascular alterations and possible clinical implications.
    Pieringer H; Pichler M
    QJM; 2011 Jan; 104(1):13-26. PubMed ID: 21068083
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Use of leflunomide plus TNF-α inhibitors in rheumatoid arthritis.
    Murdaca G; Spanò F; Puppo F
    Expert Opin Drug Saf; 2013 Nov; 12(6):801-4. PubMed ID: 23889669
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Excess cardiovascular risk in inflammatory rheumatic diseases: pathophysiology and targeted therapy.
    Onat A; Direskeneli H
    Curr Pharm Des; 2012; 18(11):1465-77. PubMed ID: 22364131
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Rheumatoid arthritis in dermatology.
    Hata T; Kavanaugh A
    Clin Dermatol; 2006; 24(5):430-7. PubMed ID: 16966022
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.